Replies to post #442639 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

“Results: In total, 39 of the 40 enrolled patients were evaluable. The injections of aDCs were well tolerated with no dose-limiting toxicities. Increased lymphocyte infiltration was observed in 54% of assessed patients. Stable disease (SD; best response) at week 8 was associated with increased overall survival. Increased secretion of interleukin (IL)-8 and IL12p40 by aDCs was significantly associated with survival (P = 0.023 and 0.024, respectively). Increased TNFa levels correlated positively with SD at week 8 (P < 0.01).

Conclusions: Intratumoral aDC injections were feasible and safe. Increased production of specific cytokines was correlated with SD and prolonged survival, demonstrating a link between the functional profile of aDCs prior to injection and patient outcomes. Clin Cancer Res; 24(16); 3845–56. ©2018 AACR.”

And let’s recall that these were all patients already in hospice with metastatic cancers most likely, and they only got one shot to one tumor.

https://clincancerres.aacrjournals.org/content/24/16/3845.long